College of Medicine, University of the Philippines Manila, Ermita, Manila, Metro Manila 1000, Philippines; Liver Cancer Unit, Fondazione Italiana Fegato - ONLUS, Basovizza, Trieste 34149, Italy.
Liver Cancer Unit, Fondazione Italiana Fegato - ONLUS, Basovizza, Trieste 34149, Italy.
Ann Hepatol. 2024 Mar-Apr;29(2):101176. doi: 10.1016/j.aohep.2023.101176. Epub 2023 Nov 14.
Liquid biopsy, specifically the analysis of circulating tumor DNA (ctDNA), offers a non-invasive approach for hepatocellular carcinoma (HCC) diagnosis and management. However, its implementation in the clinical setting is difficult due to challenges such as low ctDNA yield and difficulty in understanding the mutation signals from background noise. This review highlights the crucial role of artificial intelligence (AI) in addressing these limitations and in improving discoveries in the field of liquid biopsy for HCC care. Combining AI with liquid biopsy data can offer a promising future for the discovery of novel biomarkers and an AI-powered clinical decision support system (CDSS) can turn liquid biopsy into an important tool for personalized management of HCC. Despite the current challenges, the integration of AI shows promise to significantly improve patient outcomes and revolutionize the field of oncology.
液体活检，特别是循环肿瘤 DNA（ctDNA）的分析，为肝细胞癌（HCC）的诊断和管理提供了一种非侵入性的方法。然而，由于 ctDNA 产量低和难以从背景噪声中理解突变信号等挑战，其在临床环境中的实施较为困难。本综述强调了人工智能（AI）在解决这些局限性以及提高 HCC 护理领域液体活检发现方面的关键作用。将 AI 与液体活检数据相结合，为发现新的生物标志物提供了广阔的前景，而 AI 驱动的临床决策支持系统（CDSS）可以将液体活检转化为 HCC 个性化管理的重要工具。尽管存在当前的挑战，但 AI 的整合有望显著改善患者的预后，并彻底改变肿瘤学领域。
